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Abstract 
The aim of this work was to evaluate the potential application of an original oral 
immunotherapy, based on the use of nanoparticles, against an experimentally induced 
peanut allergy. In this context, a roasted peanut extract, containing the main allergenic 
proteins, were encapsulated into poly(anhydride) nanoparticles. The resulting peanut-
loaded nanoparticles (PE-NP) displayed a mean size of about 150 nm and a significantly 
lower surface hydrophobicity than empty nanoparticles (NP). This low hydrophobicity 
correlated well with a higher in vitro diffusion in pig intestinal mucus than NP and an 
iŵpoƌtaŶt iŶ ǀiǀo Đapaďility to ƌeaĐh the iŶtestiŶal epitheliuŵ aŶd Peyeƌ’s patĐhes. 
The immunotherapeutic capability of PE-NP was evaluated in a model of pre-sensitized 
CDI mice to peanut. After completing therapy of three doses of peanut extract, either 
free or encapsulated into nanoparticles, mice underwent an intraperitoneal challenge. 
Anaphylaxis was evaluated by means of assessment of symptom scores and mouse 
mast cell protease-1 levels (mMCPT-1). PE-NP treatment was associated with 
significant lower levels of mMCPT-1, and a significant survival rate after challenge, 
confirming the protective effect of this formulation against the challenge. In summary, 
this nanoparticle-based formulation might be a valuable strategy for peanut-specific 
immunotherapy. 
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1. Introduction 
Food allergy has been defined as adverse reactions to food in which immunologic 
mechanisms have been demonstrated [1]. In general, this type of allergy results when 
the immune system mistakenly targets a harmless food protein (allergen) as a threat 
due to the presentation of the allergen to T-cells in presence of Interleukin 4 (IL-4). 
Then, the naïve T lymphocyte starts its differentiation to a Th2 cell [2]. These Th2 cells 
produce more IL-4, IL-5 and IL-13 that encourage the production of IgE [2]. Then at the 
elicitation phase, upon a new exposure to the antigen, allergen becomes attached to 
the IgE linked to FĐεRI oŶ the suƌfaĐe of effeĐtoƌ Đells ;ŵast Đells, eosiŶophils aŶd 
basophils), triggering the rapid release of proinflammatory mediators, generally within 
minutes, including histamine and leukotrienes that cause the symptoms of allergy [3]. 
Food allergy can result in considerable morbidity, impact negatively on quality of life, 
and prove costly in terms of medical care. In principle, an allergic reaction to food can 
affect the skin, the gastrointestinal tract, the respiratory tract, and, in the most serious 
cases, the cardiovascular system [4]. Allergic reactions can range from mild (hives, 
eczema, dyspepsia, diarrhoea, angioedema, nasal congestion, etc.) to severe 
(obstructive swelling of the lips, tongue and/or throat, chest pain, weak pulse, loss of 
consciousness, etc.) [5]. Severe symptoms alone or in combination with milder 
symptoms may be signs of a potentially life-threatening condition known as 
anaphylaxis [5]. Symptoms typically appear within minutes to several hours after 
eating the culprit food [6]. Fortunately, anaphylactic shock is rarely to happen in 
response to allergic food compared with more frequent skin rashes or allergic 
symptoms in the gastrointestinal tract [7]. Although nearly any food is capable of 
causing an allergic reaction, more than 85% of these disorders are related to the 
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ingestion of milk, egg, peanut, tree nuts, shellfish, fish, wheat, sesame seed and 
soy [8]. Allergies to milk, egg, soy and wheat, are usually outgrown within the first ten 
years of life [9]. In contrast, allergies to peanut, tree nuts, fish, and shellfish tend to be 
lifelong disorders. Peanut and tree nuts are responsible for the most serious allergic 
reactions and food-allergy related fatalities [10]. 
Currently, the only available management in food allergy is the strict avoidance of the 
culprit food [11]. However this nutritional intervention approach is risky and has to be 
complemented with training on the recognition of unexpected reactions and their 
management. For patients at risk of experiencing a severe reaction (anaphylaxis) self-
injectable epinephrine is prescribed [12]. In spite of this, severe accidental reactions 
are common owing to the ubiquitous use of some of these allergens (especially 
peanut, milk and egg). Nevertheless, in the last years, important efforts to develop 
effective methods to protect food allergic individuals from severe reactions have been 
made. Among other important strategies, allergen immunotherapy is being 
investigated [13,14]. Allergen immunotherapy is based on the continuous 
administration of small amounts of the allergen in order to provide protection against 
the allergic symptoms and inflammation associated with the natural exposure to the 
allergen [15]. If the therapy is effective, ideally, the food can be consumed in normal 
quantities with no symptoms. 
In this context, the use of polymer nanoparticles may be a good strategy to develop 
effective oral treatments for food allergies. These particulate delivery systems offer 
interesting abilities as adjuvants, since they boost the delivery of the loaded antigen to 
the gut lymphoid cells, due to their ability to be captured and internalized by cells of 
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the GALT [16]. As a consequence, a strongest and more appropriate immune response 
may be obtained.    
Among others, nanoparticles based on poly(DL-lactide-co-glycolide) (PLGA)  [17], 
chitosan [18] or poly(anhydride) [19] have given encouraging results for mucosal 
allergen delivery. Particularly interesting would be the use of nanoparticles based on 
the copolymer of methyl vinyl ether and maleic anhydride (Gantrez AN). These 
poly(anhydride) nanoparticles allow effective immune responses associated with 
increased Th1 responses [20,21]. This effect would be related with the agonist 
capability of these nanoparticles of various Toll-like receptors (TLRs) (TLR2, -4, and -5), 
triggering a Th1-profile cytokine release (gamma interferon, IL-12) [22]. 
The general aim of this work was to evaluate the rational and potential application of 
these poly(anhydride) nanoparticles for oral immunotherapy. For this purpose, 
nanoparticles loaded with a peanut protein extract were evaluated in a peanut 
sensitized mice model. 
 
2. Material and Methods 
2.1. Chemicals  
Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) (Gantrez® AN119) was 
supplied by Ashland, (Ashland, USA). Peanut crude roasted extract was kindly provided 
by Diater® Laboratories SA (Madrid, Spain). Ethanol and rose Bengal were provided by 
Panreac (Barcelona, Spain). Acetone was obtained from (VWR-Prolabo). Mannitol, 
cholera toxin and Tween 20 were from Sigma-Aldrich (Germany). Lumogen® F red 305 
was from Kremer (Aichstetten, Germany). Tissue-Tek® OCT compound was obtained 
from Sakura (Alphen, Netherlands) 4´, 6-diamidino-2-phenylindole (DAPI) was obtained 
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from Biotium Inc. (Hayward, CA).  Micro-BCA™ PƌoteiŶ Assay ReageŶt Kit ǁas fƌoŵ 
Pierce® (Rockford, USA).  Deionized reagent water (18.2 Mcm resistivity) was prepared 
by a water purification system (Wasserlab, Pamplona, Spain).  Nitrogen gas (ultrapure, 
> 99) was produced using an Alltech nitrogen generator (Ingeniería Analítica, 
Barcelona, Spain). ELISA kit (mMCPT-I ELISA Ready-SET-Go! ® was from Affymetrix 
eBioscience, Inc. (San Diego, CA, USA),  
Veratox Peanut Kit was from Neogen (Lansing, MI, USA) and CAPITAN MANI soft 
peanut butter was from Alimentación Varma, S.L. (Alcobendas, Madrid). Sodium 
hydroxide (NaOH) was from Scharlau (Spain). All other materials were quality analysis. 
 
2.2. Peanut extract dialysis   
Prior the encapsulation of the peanut extract in nanoparticles, crude roasted samples 
received from the supplier (Diater Laboratories SA) were dialysed in order to remove 
the existing salts. For this purpose, the peanut extract was dispersed in deionised 
water and transferred to a dialysis bag (MWCO 3500). The bag was introduced into a 
vessel with 15 mL water and maintained under agitation for 48 h at 8°C. Finally, the 
bag contents were transferred to vials and lyophilized in a Genesis 12 EL apparatus 
(Virtis, USA). For experimental studies, only the dialyzed peanut extract (PE) was used.  
 
2.3. Preparation of peanut extract-loaded nanoparticles (PE-NP) 
Poly(anhydride) nanoparticles were prepared by a solvent displacement method [16, 
17], with some minor modifications. Briefly, 3 mg of the dialyzed peanut extract (PE) 
was first dispersed in 100 µL purified water (pH adjusted to 3.0 with HCl 0.1 N) before 
dispersion in 1 mL acetone. Then, this PE preparation was added to 4 mL acetone 
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containing 100 mg Gantrez® AN119. Nanoparticles were obtained by the addition, 
under agitation, of 10 mL of a hydroalcoholic mixture (EtOH 50% by vol.). The organic 
solvents were eliminated by evaporation under reduced pressure (Büchi R-144, 
Switzerland) and the nanoparticles were purified by ultracentrifugation (Sigma 3K30 
Rot. 12150-H, UK) at 4ºC and 21,000 rpm for 20 minutes. Finally, nanoparticles were 
resuspended in 3 mL of an aqueous solution of mannitol (2% w/v) and dried by spray-
drying in a Büchi Mini Spray Drier B-290 apparatus (Büchi Labortechnik AG, 
Switzerland). The parameters selected for this purpose were: inlet temperature of 90 
ºC, outlet temperature of 60 ºC, spray-flow of 600 mL/h, and aspirator rate at 100% of 
the maximum capacity.  
For the fluorescently labelling of nanoparticles, 4 mg Lumogen® F red 305 was added 
to the acetone solution containing the poly(anhydride). Then, nanoparticles were 
prepared, purified and dried as described above. 
As control, empty poly(anhydride) nanoparticles were prepared as described above 
but in the absence of peanut extract. These nanoparticle formulations are identified as 
NP. 
 
2.4. Physico-chemical characterization of nanoparticles 
2.4.1. Size, polydispersity index, zeta potential and yield 
The particle size, polydispersity index (PDI) and zeta-poteŶtial ;ζͿ ǁeƌe deteƌŵiŶed ďy 
photon correlation spectroscopy (PCS) and electrophoretic laser Doppler anemometry, 
respectively, using a Zetasizer analyser system (Brookhaven Instruments Corporation, 
New York, USA). The diameter and polydispersity index (PDI) of the nanoparticles were 
determined after dispersion in ultrapure water (1/10) and measured at 25ºC by 
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dynamic light scattering angle of 90°C. The zeta potential was determined as follows: 
200 μL of the samples was diluted in 2 mL of a 0.1 mM KCl solution adjusted to pH 7.4. 
The yield of the preparative process of nanoparticles was calculated by gravimetry 
[23].  
2.4.2. Peanut extract analysis 
The PE loading in the resulting nanoparticles was quantified by microBCA. For 
quantification, the amount of peanut protein associated with the nanoparticles was 
measured using the bicinchoninic acid method (MicroBCA), as previously described 
[20].  Each sample was assayed in triplicate and results of PE loading were expressed as 
the amount of protein (in µg) per mg NP. The eŶĐapsulatioŶ efﬁĐieŶĐy ;EEͿ expressed 
as a percentage was calculated as the difference between the initial amount of PE 
added and the amount of protein quantified as entrapped in the resulting 
nanoparticles. 
2.4.3. Surface hydrophobicity evaluation     
In order to evaluate the surface hydrophobicity of empty and loaded nanoparticles  the 
Rose Bengal test was performed [24], with some minor modifications. Briefly, 200 µL 
of nanoparticle suspensions (from 0.03 to 3 mg/mL) were mixed with 400 µL of a Rose 
Bengal aqueous solution (100 µg/mL). All samples were incubated under constant 
shaking at 1500 rpm, for 30 min at 25ºC (Labnet VorTemp 56 EVC, Labnet 
International, Inc.). Afterwards, the samples were centrifuged at 13,500 x g for 30 min 
(centrifuge MIKRO 220, Hettich, Germany). The amount of Rose Bengal in the 
supernatants was extrapolated from the absorbance detected at 548 nm by using a 
microplate reader (BioTek PowerWave XS, USA). Further, the total surface area of each 
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sample was plotted against the partitioning quotient (PQ) calculated in accordance 
with the following equation: 
PQ= (Rose Bengal Bound/ Rose Bengal unbound)  [Equation 1] 
2.4.4. Stability 
The stability of nanoparticles was evaluated by measuring the turbidity changes as a 
function of time in simulated gastric (SGF) and intestinal fluids (SIF). Analysis was 
performed for empty and loaded nanoparticles and stability was estimated over 2 
hours in the corresponding fluids prepared according European pharmacopeia [25].  
Briefly, nanoparticles were first dispersed in purified water (6 mg/mL). Then, each 
suspension was mixed with a similar volume of either simulated gastric or intestinal 
fluid (1:1 v/v). The turbidity changes were monitored in a spectrophotometer at 405 
nm in continuous kinetic measurements during 2 hours (Labsystems EMS Reader MF). 
All measurements were performed in triplicate, and the results were expressed as 
percentage of absorbance reductions vs. time. The percentage of absorbance 
reduction was calculated as follows (% reduction):  
% Reduction=(A0-At/A0) ×100 [Equation 2] 
Where A0 is the initial absorbance of the sample, and At is the absorbance of the 
sample at each time point.  
 
2.5. In vitro release 
The release studies were performed under sink conditions by using simulated gastric 
(SGF) and intestinal fluids (SIF), supplemented with Tween 20 (1% w/v). For these 
purposes Float-A-Lyzer devices with a MWCO of 300 kDa (Float-A-Lyzer® G2, Spectrum 
Laboratories) were used. The dialysis bags were filled with 21.6 mg nanoparticles 
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dispersed in 5 mL SGF and, then, placed into a vessel containing 660 mL SGF. The 
vessel was maintained under magnetic agitation and, at fixed time intervals, 200 µL 
samples were withdrawn and replaced with equal volumes of free SGF. After two 
hours of incubation in the gastric fluid, the device was transferred to a second vessel 
with 660 mL SIF. Again, at fixed times, 200 µL were withdrawn and replaced with free 
SIF.  
The amount of PE released from nanoparticles was quantified by ELISA with a 
commercial kit for peanut allergens (Veratox®, Neogen, Scotland, UK). 
 
2.6. In vitro evaluation of nanoparticles diffusion in mucus  
The diffusion of nanoparticles through intestinal mucus, as an in vitro measurement of 
their mucus-permeating properties, was assessed by the Multiple Particle Tracking 
(MPT) technique [26]. MPT involves video capturing and post-acquisition analysis for 
the individual movement of hundreds of fluorescently labelled particles within a mucus 
matrix [27].  
In these experiments, pig intestinal mucus was collected from freshly excised intestine. 
Samples of mucus (0.5 g) were incubated in glass-bottom MatTek imaging dishes at 37 
°C. Then, 25 µl of 0.002% fluorescently labelled nanoparticles suspensions were 
inoculated into each 0.5 g mucus sample. Each sample was incubated for 2 hours prior 
video microscopy in order to ensure effective particle distribution after inoculation.  2-
dimensional videos were captured in Leica DM IRB wide-field epifluorescence 
microscope (x63 magnification oil immersion lens) using a high speed camera (Allied 
Vision Technologies, UK) capturing 30 frames/second; 10 seconds videos (i.e. complete 
video comprised 300 frames). For each 0.5 g mucus sample, minimum of 100 individual 
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trajectories were tracked and analysed. MPT analysis for each nanoparticles species 
was carried out in triplicate (i.e. 3 mucus samples each with 100 particles and overall 
of 300 particles).   
Videos were analysed by Fiji ImageJ software to convert the movement of each 
nanoparticle into individual trajectories which is converted into metric distances in the 
X-Y directions. The distances moved by each individual particle over time were 
expressed as paƌtiĐle’s squared displacement (SD). The mean square displacement 
;M“DͿ of aŶy siŶgle paƌtiĐle ƌepƌeseŶts the ŵeaŶ of that paƌtiĐle’s sƋuaƌed 
displacements throughout its entire 30-frame trajectory. MSD was determined as 
follows: 
MSD= (XΔt)2+(YΔt)2 [Equation 4] 
 
In any single mucus sample, ensemble MSD <MSD> was determined by calculating the 
geometric mean for at least 120 individual particles. The Effective Diffusion Coefficient 
(Deff) for a particular nanoparticle type was then calculated by: 
Deff= <MSD> /4 x Δt      [Equation 5] 
Where 4 is a constant relating to the 2-dimensional mode of video capturing and Δt is 
the selected time interval. 
 
In order to express the diffusion of nanoparticles after normalising the nanoparticles 
size, the diffusion of particles was presented as a % ratio [Deff]/[D°] where D° is the 
absolute diffusion of particles in water depending on their particle sizes and calculated 
by the Stokes–Einstein equation as follows:   
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D°=κT/6πȠr        [Equation 6] 
IŶ ǁhiĐh κ is the BoltzŵaŶŶ ĐoŶstaŶt, T is aďsolute teŵpeƌatuƌe, Ƞ is ǁateƌ ǀisĐosity 
and r is the mean radius of nanoparticles. 
 
2.7. Biodistribution of nanoparticles    
Experiments were performed in compliance with the regulation of the Ethics 
Committee of the University of Navarra in line with the European legislation on animal 
experiments following a protocol previously approved [28].  For this purpose, 10 mg of 
fluorescently labelled nanoparticles were administered orally by gavage to the animals 
in order to visualize their presence in close contact with the mucosa. Then, after 2 
hours the animals were sacrificed by cervical dislocation and the gut was removed. 
Different portions of the gut were collected, cleaned with PBS, stored in OCT and 
frozen at -80 ºC. Each portion was then cut into 5 µm sections on a cryostat and 
attached to glass slides. Finally, these samples were fixed with formaldehyde and 
incubated with DAPI for 15 min before the cover assembly. The presence of both 
fluorescently loaded nanoparticles in the Intestinal mucosa and the cell nuclei dyed 
with DAPI were visualized in a fluorescence microscope (Axioimager M1, Zeiss) with a 
coupled camera (Axiocam ICc3, Zeiss) and fluorescent source (HBO 100, Zeiss. The 
images were captured with the software ZEN (Zeiss). 
 
2.8. Protective studies 
Experiments were performed in compliance with the regulation of the Ethics 
Committee of the University of Navarra in line with the European legislation on animal 
experiments (approved protocol 006/15). 
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CDI female mice of about 20 grams were sensitized by orally administration of peanut 
butter (CAPITAN MANI soft peanut butter; 4.35 mg with an approx. content of 1 mg 
protein) and 5 µg cholera toxin in a total volume of 200 µL of saline solution on days 1, 
7, 15 and 21. Moreover it was applied a tape stripping to obtain a higher sensitization 
[29]. Mice were shave and barrier-disrupted on back skin. Percutaneous sensitization 
in the damaged skin was performed by topical application of 100 µg peanut extract in 
100 µL saline solution onto the barrier-disrupted skin. 
On days 25, 28 and 35 the animals received one oral dose of 1 mg peanut extract 
either resuspended in purified water or incorporated into nanoparticles. Finally, on 
days 44 and 45 animals were challenged by an injection of 2 mg PE in 200 µL of saline 
solution by intraperitoneal route in order to provoke an anaphylactic shock in the 
sensitized animals.  
In order to analyse the intensity of the anaphylaxis shock the following parameters 
were recorded: body temperature, mobility, bristly hair and cyanosis.  
Clinical anaphylactic reactions were scored by two independent observers. Piloerection 
and cyanosis were scored as folloǁs: ;−Ϳ absent (normal mouse), (+) weak reaction 
and/or scratching of the nose and head, (++) moderate, and (+++) strong. In a similar 
way, the mobility of animals was scored as very low (no reaction after pushing), low 
(arched back and low movements) or normal. 
Furthermore, levels of mouse mast cell protease-1 (mMCPT-1) in serum were 
measured with an mMCPT-1 enzyme-linked immunosorbent assay kit, following the 
manufacturer's instructions.         
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2.9. Statistical analysis 
The physico-chemical characteristics of nanoparticles as well as the in vitro studies 
were compared using the Student´s t test. For in vivo studies, comparisons were 
performed using the one-way analysis of the variance (ANOVA) and Tukey HSD test. In 
all cases p<0.05 was consider as a statistically significant difference.  All calculations 
were performed using Graphpad Prism v6 (Graphpad Software, San Diego, CA). The 
Kaplan-Meyer curves were used for analysis of the efficacy experiment using OriginPro 
8.5  
 
3. Results 
3.1. Preparation and characterization of peanut extract-loaded nanoparticles 
Previous to characterization, the commercial peanut extracts were dialyzed in order to 
remove and eliminate phosphates, calcium salts and other divalent cations that 
negatively affect to the formation of poly(anhydride) nanoparticles.  
Table 1 summarizes the main physico-chemical characteristics of the nanoparticles 
employed in this study. The encapsulation of PE in nanoparticles decreased 
significantly the mean size (150 vs. 178) and negative zeta potential (-35 vs. -43 mV) of 
the resulting nanocarriers. Furthermore, the PE loading was calculated to be close to 
14 µg per mg nanoparticles, with an encapsulation efficiency of about 50%.  
The surface hydrophobicity of nanoparticles was evaluated by using the Rose Bengal 
test. The data are plotted as total surface area against the partitioning quotient and 
the parameter that identifies the hydrophobicity of the NPs is the slope of each line, 
the steeper the slope the higher the hydrophobicity. As presented in Figure 1, empty 
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nanoparticles were significantly more hydrophobic than PE-NP (p<0.001) and displayed 
a slope 5-fold higher than for loaded nanoparticles. 
The in vitro stability of nanoparticles was evaluated after incubation in simulated 
gastric (SGF) and simulated intestinal fluids (SIF) in a concentration of 3mg/mL (Figure 
2). In case of SGF, NP and PE-NP were stable for at least 2 hours. On the contrary, 
when nanoparticles were dispersed in SIF, the absorbance of the suspensions 
decreased rapidly, although, this decrease was more pronounced for NP than for PE-
NP.  
Figure 3 shows the release profile of PE from nanoparticles as function of time when 
incubated in SGF (during the first 2 hours), and SIF (from 2 to 24 hours) in sink 
conditions. In SGF only about 10% of the PE content was released during the first 2 
hours of the experiment. In SIF, the release rate of PE from nanoparticles increased 
during the first 8 hours, when a plateau was reached. At the end of the experiment 
(24h) only about 40% of the PE content was released from the nanoparticles.   
 
3.2. Evaluation of nanoparticle diffusion in mucus and biodistribution   
Table 2 shows the theoretical intrinsic free Brownian motion of nanoparticles in water, 
the diffusion coefficient in intestinal mucus (Deff) measured by MPT and the ratio as 
percentage of these two parameters (Deff/D°). This last parameter was employed to 
compare the diffusion of the nanoparticles in intestinal pig mucus after normalising 
the effect of particle size. For PE-NP, the diffusion capability in the mucus was found to 
be 2.25-fold higher than for empty nanoparticles (NP).  
Figure 4 shows fluorescence microscopy images of ileum samples from animals treated 
with fluorescently labelled nanoparticles two hours post-administration. Empty 
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nanoparticles displayed a restricted localization at the mucus layer and a large amount 
of the formulation was visualized in the lumen with no interaction with the mucosa. 
On the contrary, the fluorescence associated to peanut-loaded nanoparticles was 
mainly observed in areas close to the intestinal villi of mucosa. In addition, PE-NP 
displayed also an interesting capability to interact with Peyer´s Patches (PP).  
 
3.3. Protective studies 
Peanut sensitized animals received an immunotherapeutic schedule on days 4, 7, and 
14 after sensitization. Then, on day 20, animals were challenged with the 
intraperitoneal administration of 2 mg peanut extract. In order to analyse the intensity 
of the anaphylaxis, several parameters were evaluated. Figure 5 shows the body 
temperature in the laboratory animals, 10 minutes after challenge. Sensitized- and non 
-treated animals (Control +) experienced an important decrease of their body 
temperature. Interestingly, animals treated either with free (PE) or encapsulated (PE-
NP) peanut extract displayed a significantly lower temperature variation (p<0.05). 
Twenty minutes after challenge, mice were visually assessed for symptoms of 
anaphylaxis and assigned symptoms scores (Table 3). Piloerection and cyanosis 
seemed to be similar for animals treated with either PE or PE-NP. Moreover, animals 
from the non-treated group (Control +) were found completely static with a high 
difficulty to coordinate any simple movement, whereas treated animals were able to 
coordinate to some extent simple movement or react against pain or pressure in a 
similar way. Moreover, 20 min post-challenge, the body temperature of sensitized 
animals maintained a significantly lower body temperature than the basal one. This 
temperature decrease was higher for non-treated (Control +) and PE-treated animals 
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than for those animals treated with PE-NP. Non-sensitized animals displayed a normal 
behaviour with no symptoms of anaphylaxis.  
Figure 6 shows the mouse mast cell protease-1 (mMCPT-1) levels on the sera of 
animals 15 minutes after challenge. Non-sensitized animals displayed lower values of 
this protease, similar to constitutive expression found in the bibliography [30–32]. 
Animals treated with PE-NP displayed similar serum levels of mMCPT-1 than non-
sensitized animals. In addition, these protease levels were significantly lower than 
those quantified in animals ascribed to the positive control group or the PE treated 
group (p<0.001).  
Figure 7 shows the cumulative survival of animals after the intraperitoneal 
administration of 2 mg PE. In the control group, all the non-sensitized animals survived 
to this challenge. On the contrary, one day after challenge, all the animals included in 
the positive control and PE groups died. For the sensitized animals treated with PE-NP, 
the survival rate 24 h post-challenge was calculated to be of 40%.   
 
4. Discussion 
In previous studies, our research group evaluated the immunogenicity of PE-loaded 
nanoparticles suggesting their potential for oral immunotherapy purposes due to their 
pro-Th1 adjuvant properties. Thus, one single dose of PE-loaded nanoparticles induced 
in mice a balanced Th1 and Th2 antibody response, accompanied by a low specific IgE 
induction and high serum levels ofIFN-ɣ and IL-10 [33]. In the present work, similar 
nanoparticles have been prepared in order to gain insight about their behaviour in vivo 
and their protective capability against a challenge in peanut sensitized animals. In this 
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particular work a roasted crude extract of peanut was employed after purification by 
dialysis [34]. 
The purified extract was then encapsulated into poly(anhydride) nanoparticles (150 
nm and -35 mV), with a payload of 14 µg peanut extract per mg nanoparticles (Table 
1). Overall, these physico-chemical properties were similar to those described 
previously by Rebouças and co-workers [20,35]. On the other hand, the encapsulation 
of the peanut extract produced nanoparticles (PE-NP) with a significantly lower 
hydrophobicity than empty nanoparticles (Table 1). This finding, as well as the 
reduction in the negative zeta potential of the loaded nanoparticles (-35 mV for PE-NP 
vs. -43 mV for NP, table 1) suggested that some of the component of the peanut 
extract would be localized in the outer layer of the resulting nanocarriers. This 
decrease of the surface hydrophobicity for PE-loaded nanoparticles correlated well 
with higher diffusion in intestinal mucus than for empty nanoparticles (Table 2). 
Among other characteristics, for nanocarriers, a lower surface charge and a lack of 
hydrophobic regions/domains have been related with a reduced interaction with 
mucus [36,37]; facilitating the development of nanoparticles with mucus-permeating 
properties. In our case, and due to the presence of protein components of the peanut 
extract on the surface of nanoparticles, PE-NP exhibited 2.3-fold higher diffusion 
through the mucus network in comparison with control NP. This higher diffusivity of 
PE-loaded nanoparticles in the mucus was also corroborated in the biodistribution 
study with fluorescently labelled nanoparticles. Thus, NP displayed mucoadhesive 
properties with a distribution restricted to the mucus layer of the intestinal mucosa 
(Figures 4C and 4D), whereas PE-NP were capable of reaching the intestinal epithelium 
and the surface of Peyer`s Patches (Figures 4A and 4B, respectively). Peyer’s Patches 
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are primary inductive sites of mucosal immunity located in mammalian small intestine 
[38]. In fact, They have been extensively studied for their contribution to mucosal 
tolerance, although their role is still unclear [39]. IŶ aŶy Đase, the taƌgetiŶg of Peyeƌ’s 
patches would be desirable for the modulation of tolerance [40]. 
On the other hand, PE-NP displayed gastro-resistant properties with a relatively rapid 
degradation under simulated intestinal conditions (figure 2). This behaviour agrees 
well with the release profile of the peanut extract from nanoparticles. Nevertheless, at 
the end of the experiment, only 40% of the loaded extract appeared to be released 
(Figure 3). This apparent anomalous result maybe related with the capability of 
GaŶtƌez AN of estaďlishiŶg ͞stƌoŶg͟ ioŶiĐ aŶd ĐoǀaleŶt iŶteƌaĐtioŶs ǁith ĐoŵpouŶds 
possessing ionisable residues and/or primary amine groups [41,42]. These interactions 
would induce changes on the conformation of peanut proteins that would reduce the 
sensitivity of the ELISA analysis. In any case, these possible links between the 
poly(anhydride) and peanut proteins should be elucidated in a next future study. 
The immunotherapeutic capability of PE-NP was evaluated in a model of pre-sensitized 
mice to peanut. Once the animals were sensitized, the nanoparticles were 
administered to the mice and afterwards they were intraperitoneally challenged with 
the peanut extract. Regarding the anaphylactic symptoms, only animals treated with 
the PE-NP displayed a significantly lower decrease in their basal temperature when 
compared with animals treated with PE or ascribed to the positive control group (table 
3). Another interesting finding was the similar mMCPT-1 (mouse mast cell protease 1) 
levels in the sera of sensitized animals treated with PE-NP, when compared with 
normal animals (negative control group) (Figure 6). mMCPT-1 is a chymase expressed 
by intestinal mucosal mast cells, which are found in the intestinal epithelium [43]. 
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Elevated mMCPT-1 levels are observed during intestinal allergic hypersensitivity 
reactions. Thus, these sera levels of the protease would be directly related with the 
severity of the anaphylactic shock [44]. 
In line with these results, a significant fraction of animals treated with PE-NP survived 
24 hours after ip challenge (Figure 7); confirming the protective effect of this 
formulation against the challenge. In terms of clinical use, a nanoparticle-based 
immunotherapy with an improved efficacy than the current daily doses of allergens, 
would facilitate the implementation of safer regimens and its adaptation to individual 
patieŶts’ Ŷeeds aŶd theiƌ pƌogƌessioŶ oǀeƌ tiŵe.  
In summary, we have corroborated the ability of poly(anhydride) nanoparticles to load 
and carry a peanut extract, facilitating their biodistribution within the gut, including 
Peyer`s Patches. In addition, this nanoparticle-based formulation offers a promising 
protection against the effects induced by an anaphylactic shock in peanut sensitized 
animals, opening the door to a future clinical employment. 
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Illustrations 
 
 
 
Figure 1. Hydrophobicity of empty and peanut-loaded nanoparticles. Partition 
Quotient (PQ) versus total surface area (TSA) of nanoparticles. Values expressed as the 
mean ± SD (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Stability of empty (NP) or peanut loaded nanoparticles (PE-NP) in simulated 
gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 6.8). Data expressed as 
mean ± SD (n=3). 
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Figure 3. In vitro release of peanut extract from PE-NP. Data expressed as cumulative 
amount of PE released versus time. Samples were incubated for 2 hours in SGF, and 
then samples were transferred to SIF till the end of the experiment. Data expressed as 
mean ± SD (n=3).  
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Figure 4. Fluorescent microscopic visualization of Lumogen red-loaded nanoparticles in 
longitudinal sections of the ileum of rats. Images A and B correspond with peanut 
extract-loaded nanoparticles (PE-NP), whereas images C and D show the distribution of 
NP. The draw in the middle indicates the anatomical regions for the mucosal intestinal 
villi (M), the follicle-associated epithelium of Peyer`s Patches (PP), and Lumen (L). 
Arrows in figures A and B indicate the intestinal portions with high interaction between 
nanoparticles and mucosal intestinal villi. DAPI staining of nuclei appears as blue. 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Body temperature after allergic provocation challenge in peanut-sensitized 
mice. Mice were treated with empty nanoparticles (NP) or peanut-loaded 
nanoparticles (PE-NP). A group of sensitized untreated mice (control +) and a group of 
non-sensitized mice (control -) were also included. Data show individual temperature 
and mean. (* p<0.05 and ***p<0.001 vs. Control +). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Sera levels of mMCPT-1 after allergic provocation challenge in peanut-
sensitized mice. Mice were treated with empty nanoparticles (NP) or peanut-loaded 
nanoparticles (PE-NP). A group of sensitized untreated mice was also included. A group 
of sensitized untreated mice (control +) and a group of non-sensitized (control -) were 
also included. Serum samples were taken 15 minutes after challenge. Data are shown 
as mean ± SD. ***P<0.001 vs. Control +. 
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Figure 7. Protective efficacy of the oral immunotherapy based on a peanut extract 
administered either free (PE) or encapsulated into nanoparticles (PE-NP).  Mice were 
previously sensitized. Sensitized untreated animals (Control +) and non-sensitized mice 
(Control -) were also included as controls. The figure indicates the percentage of mice 
that survive the intraperitoneal challenge with a peanut fraction (**p<0.01, Log rank 
test indicates significant differences between animals treated with PE-NP and non-
treated control positive animals). 
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Tables  
Table 1.  Physico-chemical characteristics of PE-loaded nanoparticles. PDI: 
polydispersion index; EE: encapsulation efficiency. The degree of hydrophobicity 
corresponds with the slope of curves from Figure 1. Data expressed as mean ± SD 
(n=3).  
 
 Mean size 
(nm)a 
PDI Zeta Pot. 
(mV)b 
PE loading 
(µg/mg NP) 
EE 
(%) 
Surface 
hydrophobicity 
NP 178±2 0.14±0.06 -43±1 - - 274±2 
PE-NP 151±5 0.16±0.01 -35±1 14.0±0.7 50.3±2.6 51±2 
a p<0.01 empty versus loaded NP; b  p<0.001 empty versus loaded NP.  
 
Table 2. Nanoparticle diffusion kinetics. Data expressed as mean ± SD (n=3). D°: 
diffusion coefficient in water; <Deff>: diffusion coefficient in mucus; ratio %<Deff>/ D°: 
relative efficiency of particles diffusion; R: ratio of %<Deff>/ D° of the formulations 
tested. 
 
 D°  (water) 
cm2 x S-1 x10-9 
<Deff>  (mucus) 
cm2 x S-1 x10-9 
%<Deff>/ D° R 
NP 25.69 0.00041 (± 0.00032) 0.00160 1 
PE-NP 31.44 0.00113 (± 0.00083) 0.00360 2.25 
 
 
Table 3. Anaphylactic symptoms after allergic provocation challenge in peanut-
sensitized mice. Mice were treated with empty nanoparticles (NP) or peanut-loaded 
nanoparticles (PE-NP). A group of sensitized untreated mice was also included. A group 
of sensitized untreated mice (control +) and a group of non-sensitized (control -) were 
also included. Symptoms were scored at 20 minutes post-challenge. 
 
 Δ Temperature 
(°C) 
Piloerection Mobility Cyanosis 
Control + -4.5±0.61 +++ Very low +++ 
PE -4.4±0.8 ++ Low - 
PE-NP -2.5±1.8 ++ Low - 
No sensitization 0.5±0.8 - Normal - 
Severity symptoms: (-) absent (+) weak (++) moderate (+++) strong 
 
 
 
 
 
